[1]柳志红 段安琪 罗勤.肺动脉高压：从全球视野到国内现状[J].心血管病学进展,2024,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.001]
　LIU ZhihongDUAN AnqiLUO Qin.Pulmonary Hypertension: From a Global Perspective to the Domestic Situation[J].Advances in Cardiovascular Diseases,2024,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.001]
点击复制

肺动脉高压：从全球视野到国内现状()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年1期
页码:
1
栏目:
述评
出版日期:
2024-02-21

文章信息/Info

Title:
Pulmonary Hypertension: From a Global Perspective to the Domestic Situation
作者:
柳志红 段安琪 罗勤
(国家心血管病中心 中国医学科学院 北京协和医学院 阜外医院 呼吸与肺血管疾病诊治中心, 北京100037)
Author(s):
LIU ZhihongDUAN AnqiLUO Qin
Center for Respiratory and Pulmonary Vascular Diseases,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)
关键词:
肺动脉高压; 右心导管; 肺血管病
Keywords:
Pulmonary hypertension; Right heart catheterization; Pulmonary vascular disease
DOI:
10.16806/j.cnki.issn.1004-3934.2024.01.001
摘要:
肺动脉高压是一种异常的血流动力学状态，其病因复杂，进展迅速，对人类的生命健康造成了严重威胁，成为一项全球性的健康难题。肺动脉高压需根据血流动力学确诊，并进一步临床分类，多学科综合管理对于肺动脉高压的诊疗至关重要。近年来，中国在肺动脉高压领域取得了显著进展，但仍面临着诊疗规范性欠佳、医疗资源分配不均、专业医学培训不足等挑战。肺动脉高压诊疗规范性文件的发布有望提高基层医疗水平，为患者提供更全面及优质的医疗服务，从而改善患者的生存环境和生活质量。
Abstract:
Pulmonary hypertension(PH) is an abnormal hemodynamic state,with a complex etiology and rapid progression,posing a serious threat to human life and health,and becoming a global health problem. PH needs to be diagnosed based on hemodynamics and further classified clinically. Multidisciplinary comprehensive management is crucial for the diagnosis and treatment of PH. In recent years,China has made significant progress in the field of PH,but still faces challenges such as poor diagnostic and treatment standards,uneven distribution of medical resources,and insufficient professional medical training. The release of regulatory documents for PH diagnosis and treatment is expected to enhance primary healthcare capabilities,providing more comprehensive and high-quality medical services for patients,thereby improving their living environment and quality of life

参考文献/References:

[1]Hoeper MM,Humbert M,Souza R,et al. A global view of pulmonary hypertension[J]. Lancet Respir Med,2016,4(4):306-322.

[2]Humbert M,Kovacs G,Hoeper MM,et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J,2022,43(38):3618-3731.

[3]罗勤,柳志红,奚群英,等. 中国动脉型肺动脉高压患者生存现状调查[J]. 中国循环杂志,2022,37(11):1111-1115.

[4]罗勤,熊长明. 肺血管病右心导管术操作指南[J]. 中国循环杂志,2022,37(12):1186-1194.

[5]罗勤. 中国肺动脉高压诊治临床路径[J]. 中国循环杂志,2023,38(7):691-703.

相似文献/References:

[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
　MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(1):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
　ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
　WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(1):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
　WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(1):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
　DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(1):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
　ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(1):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
　ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(1):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
　HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(1):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
　LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(1):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
　Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(1):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
[11]李欣 王惠桐 柳志红 赵智慧 罗勤 赵青.运动诱导的肺动脉高压的研究进展[J].心血管病学进展,2021,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.001]
　LI Xin,WANG Huitong,LIU Zhihong,et al.Exercise Induced Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2021,(1):865.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.001]

更新日期/Last Update: 2024-03-06